BSX February 2026 Options Begin Trading

StockOptionsChannel highlights option strategies for Boston Scientific (BSX, current price $95.81): selling the Feb‑2026 $87 put at $0.50 would set an effective purchase basis of $86.50 (≈9% below current price) with a 79% chance to expire worthless and a 0.57% return (4.77% annualized) if so. Conversely, selling a $97 covered call at $1.35 while owning shares would cap proceeds at $97 for a 2.65% total return if called, has a 51% chance to expire worthless, and would provide a 1.41% premium boost (11.69% annualized). Implied volatilities are cited at 40% for the put and 28% for the call versus a 24% trailing‑12m realized volatility; the site will track odds and contract trading history over time.

Analysis

Market structure: The option quotes show modestly rich protection (put IV 40% vs call IV 28% and spot vol 24%), signaling asymmetric investor demand for downside insurance on BSX (Boston Scientific). That makes selling the Feb‑2026 $87 put (collect $0.50 for an effective $86.50 entry, ~9% below $95.81) attractive only if you accept ~21% probability of assignment; covered calls ($97 strike, $1.35) monetise 1.4% yield but cap ~1–3% upside to Feb‑26. The skew compresses potential upside capture for aggressive buyers while providing income trades for carry-sensitive allocators.

Risk assessment: Near term (days–weeks) the biggest risks are IV spikes from clinical/FDA news or headline litigation that can rerate put prices >2x; medium term (months) reimbursement or supply disruptions could drive >15% moves; long term (quarters+) device adoption and competitive losses could structurally lower margins. Hidden dependency: option P/L profiles hinge on IV path — a 20–30 point IV jump on puts would make naked short puts toxic. Key catalysts: upcoming earnings, trial/FDA updates, and general risk‑off events (rates/credit) that historically move medtech stocks +/-10–20%.

Trade implications: If you want equity exposure, implement a defined‑risk approach: sell Feb‑26 $87 put while buying a protective $82 put to create a put credit spread (net premium ~+$0.50‑$0.70 depending on buys) sized to 1–2% portfolio risk; alternatively, buy BSX and sell the $97 covered call if comfortable capping upside through Feb‑26. For volatility plays, buy puts or put spreads if IV dips below 25% and impending catalysts exist; consider long BSX vs short MDT for 12–18 month idiosyncratic outperformance if you expect device share gains.

Contrarian angles: Consensus income‑seeking response underestimates tail legal/regulatory downside — the ~4.8% annualised put yield is small relative to potential single‑event losses >20%. Conversely, if IV normalises to 24% and clinical news is positive, covered calls will leave material upside on table (if BSX rallies >5–10%); historical medtech post‑trial rallies show >20% moves, so collars or call spreads may be superior to naked covered calls.

Key Decisions for Investors

• Establish a defined‑risk short put spread: sell 1x Feb‑2026 BSX $87 put and buy 1x Feb‑2026 $82 put sized to 1–2% portfolio exposure; target net credit ≥ $0.50 and cut losses if BSX < $80 (assignment probability rises materially).
• If bullish on shares, buy BSX up to a 2–3% position and sell Feb‑2026 $97 calls (covered call) to collect $1.35; be prepared to roll or accept assignment if price ≥ $97, and trim if BSX < $90 within 30 days.
• Avoid naked short $87 puts >3% portfolio size given put IV skew; instead deploy collars (buy Feb‑2026 $82 put) when selling calls to limit 1st‑order tail risk. Monitor IV: pause new short put positions if put IV >50% or if implied/realised vol spread widens >20 pts.
• Pair trade (relative value): go long BSX (2%) and short MDT (Medtronic) equal dollar notional for 6–18 months if you view BSX as having stronger device adoption; stop‑loss if BSX underperforms MDT by 8% over 60 trading days.
• Catalyst watchlist (act within 2–30 days): take or adjust positions ahead of BSX earnings and any scheduled FDA/trial announcements; if negative headlines arrive, expect IV to spike and close/hedge short premium positions immediately.